HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Lisinopril therapy for hemodialysis hypertension: hemodynamic and endocrine responses.

Abstract
To evaluate the antihypertensive effects of lisinopril, a renally excreted angiotensin-converting enzyme inhibitor, we assessed supervised administration of the drug after hemodialysis (HD) three times weekly. Blood pressure (BP) was assessed by interdialytic 44-hour ambulatory BP (ABP) monitoring, and endocrine responses were assessed by plasma renin activity (PRA) before and after dialysis. Lisinopril dose was titrated at biweekly intervals. If this was not effective after full titration (lisinopril to 40 mg three times weekly), ultrafiltration was added to reduce dry weight. The primary outcome variable was change in BP from the end of the run-in period to the end of the study. No change in mean ABP was noted during run-in. However, mean 44-hour ABP decreased from 149 +/- 14 (SD)/84 +/- 9 to 127 +/- 16/73 +/- 9 mm Hg, a decrease of 22/11 mm Hg (P < 0.001) at final evaluation. Of 11 patients who completed the trial, only 2 patients had systolic hypertension (>/=135 mm Hg) and 1 patient had diastolic hypertension (>/=85 mm Hg) at the final visit. Four patients were administered 10 mg of lisinopril; 5 patients, 20 mg; and 2 patients, 40 mg; only 1 of these patients required ultrafiltration therapy. There was a persistent antihypertensive effect over 44 hours. BP reduction was achieved without an increase in intradialytic symptomatic or asymptomatic hypotensive episodes. PRA increased in response to dialysis, as well as lisinopril. In conclusion, supervised lisinopril therapy is effective in controlling hypertension in chronic HD patients. This may be related to blockade of angiotensin II generation by kidneys despite the loss of excretory function.
AuthorsR Agarwal, R Lewis, J L Davis, B Becker
JournalAmerican journal of kidney diseases : the official journal of the National Kidney Foundation (Am J Kidney Dis) Vol. 38 Issue 6 Pg. 1245-50 (Dec 2001) ISSN: 1523-6838 [Electronic] United States
PMID11728957 (Publication Type: Clinical Trial, Journal Article)
Chemical References
  • Angiotensin-Converting Enzyme Inhibitors
  • Lisinopril
Topics
  • Adult
  • Aged
  • Aged, 80 and over
  • Analysis of Variance
  • Angiotensin-Converting Enzyme Inhibitors (administration & dosage)
  • Blood Pressure Monitoring, Ambulatory
  • Dose-Response Relationship, Drug
  • Drug Administration Schedule
  • Female
  • Hemodynamics (drug effects)
  • Humans
  • Hypertension (drug therapy, etiology, physiopathology)
  • Lisinopril (administration & dosage)
  • Male
  • Middle Aged
  • Renal Dialysis (adverse effects)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: